Immunocore vs Twist Bioscience
Twist Bioscience reported revenue of $459 million in fiscal 2026, about the same as Immunocore's $400 million in fiscal 2025. Immunocore's revenue grew 28.9% in its latest year, and Twist Bioscience's grew 22.0%. Immunocore had an operating margin of -11.3%, against -30.4% at Twist Bioscience. Free cash flow was −$15 million at Immunocore and −$89 million at Twist Bioscience. Their fiscal years end in different months (December 31 and September 30), so the periods don't line up exactly.
Side by side
| Immunocore | Twist Bioscience | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2026, Sep 30, 2026 |
| Revenue | $400M | $459M |
| Revenue growth | 28.9% | 22.0% |
| Revenue growth a year, last 5 years | — | 28.3% |
| Gross margin | 98.7% | 52.4% |
| Operating margin | −11.3% | −30.4% |
| Net margin | −8.9% | −28.3% |
| Free cash flow | −$15M | −$89M |
| Free cash flow margin | −3.8% | −19.4% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 0.7% | 4.7% |
| Last close | $26.63 | $111.62 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $5.6 million | sold $131.1 million |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
ImmunocoreTwist Bioscience
Operating margin
Percent of revenue
ImmunocoreTwist Bioscience
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
ImmunocoreTwist Bioscience
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Immunocore and Twist Bioscience pages.